Akebia Therapeutics (AKBA) Misses Q1 EPS by 2c

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $53.54 million versus the consensus estimate of $54.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Venu Holding enters $250 million at-the-market stock offering agreement
• Lantern Pharma (LTRN) files for 2.24M share offering by selling stockholders